Skip to content

NeuroRX Dr Duprez

Active
Private limited companyfounded 2023active for 2 yearsGrensstraat 195, 1950 Kraainem, BelgiumKBO/BCE: BE 1002.035.239
Summary

NeuroRX Dr Duprez has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €122,808 and a net result of €100,244. Equity is growing by about 265% per year across the filed financial years. Its solvency ranks better than 51% of 20,598 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Risk analysisFollow ReportCompare
NeuroRX Dr DuprezActiveChecked score 97/100
Risk analysis ReportCompare

Overview

Activity
Specialist medical practice
NACE 86220
1 site
Size
€191,565total assets 2025
Equity
€122,808
Profit
€100,244
Turnover not published (micro format)
Financial health
97 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
< 0.1%
Structure
2025 accounts filed 32 days late
Why 97lowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 2.77, cash €151,232Size: total assets €191,565Equity €122,808 (64.1% of total assets)Show the evidence

Checked score

Score 2025
97 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 74% of its sector peers (NACE 86, micro)
Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Strong
Solvency 89+7
equity 64.1% of total assets
Liquidity 84+12
short-term debt 35.9% · cash 78.9%
Profitability 100=
return on assets 52.3%
Bankruptcy probability, 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,117 companies, NACE 86, micro)
Last 24 months 12-2024: < 0.1% 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: 0.1%▲ +0.1 percentage points vs 04-2025 06-2025: 0.1%● unchanged vs 05-2025 07-2025: 0.1%● unchanged vs 06-2025 08-2025: 0.1%● unchanged vs 07-2025highest value 09-2025: < 0.1%▼ -0.1 percentage points vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: 0.1%▲ +0.1 percentage points vs 07-2026 09-2026: 0.1%● unchanged vs 08-2026 10-2026: < 0.1%▼ -0.1 percentage points vs 09-2026lowest value
Credit of up to €11,000 on 30-day terms, only on tighter conditions: young company (under 3 years) without a track record
Liquidity ample (current ratio 2.77, compared with 2.16 in 2024, above the usual 1.5; short-term debt: 35.9% and cash: 78.9% of total assets), and 35.9% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro): better than 52% on solvency, 66% on liquidity, 80% on profitability and 98% on growth.

The bankruptcy probability was computed on 24-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises risk
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Liquidity: current ratio 2.77, cash €151,232
NBB · annual accounts
lowers risk · Size: total assets €191,565
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
lowers risk · Equity €122,808 (64.1% of total assets)
NBB · annual accounts
raises risk · Young company
Founded in 2023, 2 years ago. Young companies fail more often than established ones; the risk is highest 2 to 8 years after founding.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 2 years 0 10 years
raises risk · 2025 accounts filed 32 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 01-09-2026, 32 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 3 filings
Deviation from the deadline
2025
32 days late
2024
13 days late
2023
44 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 3 accounts on average on the deadline day; the sector median (NACE 86) for financial year 2024 is 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 13 August (3 of the last 3 filed years within 56 days of that day).
Companies Code · seven months
Where today falls in the filing period
24-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since incorporation in 2023.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · micro…
  2. Highest result from 2023 to 2025net €100,244 ▲415%
  3. Equity above €100,000equity €122,808 ▲444%

Key points

  • Positive: Result rose in 2025from €19,459 to €100,244 ▲ 415% View
  • One director decidessole director in office 1 View
  • Total assets 20253 financial years filed €191,565 View

By topic

Financials

Financial year
2025
Total assets
€191,565
Profit
€100,244
Solvency
64.1%
Total assets▲ 384%
Net result
20232025
Go to Financials

Timeline

Events
8
Since
2023
Next accounts
by 31-07-2027
  1. 13-08-2025Annual accounts filed
  2. 31-12-2024Back to profit
  3. 31-12-2024Liquidity more than doubled
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Specialist medical practiceNACE 86220
Founded
07-11-2023
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Articles of association

Provisions read
16
Annual meeting
Second Monday of June at 18:00
Purpose
“De uitoefening van de geneeskunde,met specialisatie…” (deed in Dutch)
Go to Articles of association

Key facts about NeuroRX Dr Duprez

What is the company number of NeuroRX Dr Duprez?
1002.035.239. In Belgium the VAT number is the company number with BE in front: BE 1002.035.239.
Where is NeuroRX Dr Duprez based?
The registered office is at Grensstraat 195, 1950 Kraainem.Company details
What does NeuroRX Dr Duprez do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of NeuroRX Dr Duprez?
Private limited company (BV).
When was NeuroRX Dr Duprez founded?
On 07-11-2023.
Is NeuroRX Dr Duprez still active?
Yes, NeuroRX Dr Duprez is an active enterprise in the KBO register.
What is the turnover of NeuroRX Dr Duprez?
Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.Financials
Is NeuroRX Dr Duprez profitable?
In financial year 2025, NeuroRX Dr Duprez made a profit of €100,244.
Where can I find the annual accounts of NeuroRX Dr Duprez?
NeuroRX Dr Duprez filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of NeuroRX Dr Duprez due?
By 31-07-2027, for financial year 2026.Timeline

Companies related to NeuroRX Dr Duprez

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure